There is a second active compound in green tea that has nothing to do with antioxidants. A 2025 review just took it seriously.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
0:00
|
6:42
From Root to Ritual by Laritelle Organic.
Green tea has appeared throughout this series as an antioxidant — EGCG protecting collagen from oxidative degradation, supporting HIF-1α signalling integrity, reducing the sebum oxidation that feeds PIILIF inflammation. All of that is accurate and well-supported. It is also half the story. Green tea also contains caffeine — and a 2025 systematic review took the question of what topical caffeine do...
Read the full article: https://laritelleorganic.com/blogs/news/there-is-a-second-active-compound-in-green-tea-that-has-nothing-to-do-with-antioxidants-a-2025-review-just-took-it-seriously
SPEAKER_00
Green tea has appeared throughout this series as an antioxidant, E.G. C protecting collagen from oxidative degradation, supporting HIF 1A signaling integrity, reducing the sebum oxidation that feeds pilif inflammation. All of that is accurate and well supported. It is also half the story. Green tea also contains caffeine, and a 2025 systematic review took the question of what topical caffeine does for hair seriously enough to screen 1,121 articles down to nine qualifying clinical trials covering 684 participants with androgenetic alopecia, excessive hair loss, or hair thinning. Topical caffeine consistently demonstrated hair growth or reduced hair loss with minimal adverse effects across the trials reviewed. The authors concluded that caffeine appears to be a safe and promising potential treatment for hair loss, while noting that further large-scale randomized controlled trials with standardized outcome measures are needed. The mechanism through which caffeine operates is genuinely distinct from every other botanical compound covered in this series, and it adds a dimension to the green tea component of the formula that the EGCG antioxidant framing alone doesn't capture. The mechanism how caffeine reaches the follicle through a pathway nothing else uses. Selective non-inhibition of 5 alpha reductus. This is a careful and unusual phrase, selective non-inhibition, and it describes something specific. Phenasteride works by blocking 5-alpha reductus entirely, which is W high, it has systemic hormonal side effects. Caffeine appears to interact with the enzyme system differently, not blocking it the way phenasteride does, but modulating follicle metabolism through a separate pathway that doesn't carry the same systemic hormonal consequences. This is mechanistically distinct from bring garage, nettle, and saw palmetto, all of which work through actual 5-alpha reductacy inhibition, the same category as phenasteride but topical and botanical. Caffeine is doing something else entirely, which means it is not redundant with the DHT inhibiting botanicals already in the formula. It is operating on a parallel track. Phosphodiesterase inhibition, the CAMP connection caffeine inhibits phosphodiesterase enzymes, which normally break down cyclic AMP, CAMP, a secondary messenger molecule inside cells that regulates metabolic activity. By inhibiting the enzyme that degrades CAMP, caffeine increases intracellular CAMP levels, which stimulates metabolic activity in hair follicle cells. This connects to the energy metabolism thread running through this series. PP405 targets, the mitochondrial pyrovate carrier, HIF1A governs the metabolic shift under low oxygen, and now caffeine is shown to stimulate follicle metabolic activity through a third independent pathway. Three different mechanisms, pharmaceutical, PP405, oxygen sensing, HIF, 1A, and now a topical botanical compound, caffeine, all converge on the same broad target, follicle cellular energy and tabolic activity. This is not coincidence, it reflects how central follicle metabolism is to the growth cycle. Direct antioxidant activity, independent of EGCG caffeine, also acts as an antioxidant and may prevent degenerative processes through a mechanism independent of EGCG, the polyphenol most associated with green tea's antioxidant reputation. This means green tea is delivering two separate antioxidant mechanisms simultaneously, EGCG's polyphenol antioxidant activity and caffeine's distinct antioxidant pathway, alongside caffeine's metabolic and 5-alpha reductus effects, a single botanical ingredient, multiple independent mechanisms, microbiome and lipidome effects, the newest finding. A 2025 study in the International Journal of Cosmetic Science examined the effects of caffeine and adenosine on the scalp microbiome and lipidome. At 12 weeks, anti-hair loss effects were evident with decreased Pseudomonas, Esterichia shigella and malecedia, and increased talaromyces and cutibacterium, alongside changes in scalp lipid composition. This is the first time caffeine has been connected to the microbiome research this series covered extensively in May. The MESCH index, the relationship between cutibacterium populations, and AGA severity, the malasseia overgrowth associated with PLIF inflammation, a reduction in malecetsia and an increase in protective cutie bacterium from topical caffeine application is a microbiome-level effect that the EGCG framing of green tea, a never-captured, 684 participants across nine clinical trials, 5 RCTs, in the 2025 systematic review, topical caffeine consistently demonstrated hair growth or reduced hair loss with minimal adverse effects. Model substance. Caffeine is used as a model substance for skin barrier penetration studies, meaning its scalp delivery profile is among the best characterized of any topical compound two mechanisms in one ingredient, EGCG's polyphenol antioxidant activity, and caffeine's independent antioxidant and metabolic pathways, both delivered by green tea simultaneously. The honest caveats, what the evidence does and doesn't establish. The 2025 Systematic Review is appropriately cautious. None of the studies use tattooed or marked scalp areas for standardized hair counts, a methodological limitation that affects precision across the field, not just caffeine research specifically. Clinical research on caffeine-based therapies remains limited compared to FDA-approved treatments such as topical monoxidil, oral phenasteride, and JAC inhibitors. The authors explicitly call for further large-scale randomized controlled trials with standardized outcome measures. This is not a claim that caffeine is equivalent to minoxidil or phenasteride, or that it should replace either. It is a claim that the evidence for topical caffeine, modest in scale but consistent in direction across 684 participants and multiple trial designs, supports its inclusion as a complementary compound, working through MEC.